Review Collection on Humoral Immunity

A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Humoral Immunity".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 974

Special Issue Editors


E-Mail Website
Guest Editor
Centre de Recherche des Cordeliers, Sorbonne Université, F-75006 Paris, France
Interests: immunology; immune homeostasis; immunotherapy; host-pathogen interaction
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China
Interests: antibody; vaccine; viruses

Special Issue Information

Dear Colleagues,

The “Humoral Immunity” Section is devoted to publishing major advancements related to the antibody response in a wide variety of host species under physiological, pathological, therapeutic, and vaccination conditions. The main topics include, but are not limited to, the following:

  1. Antibody response during infections, diseases, treatments, and vaccination;
  2. Identification and evaluation of biomarkers associated with antibody production and protection;
  3. Neutralizing antibodies against pathogens and toxins;
  4. Self-reactive autoantibodies;
  5. Structure and function of clinically relevant antibodies;
  6. Physiological antibody generation as well as maturation and related mechanisms, such as antigen presentation for B cell activation, cytokine production, germinal center formation, isotype switching, affinity maturation, and long-term memory generation;
  7. Mechanisms of and interference with antibody-mediated complement activation.

In particular, we welcome submissions exploring the use of cutting-edge technologies across disciplines to provide a comprehensive overview of the mechanisms of the humoral immune response during natural development, diseases, therapy, and vaccination.

Prof. Dr. Jagadeesh Bayry
Prof. Dr. Linqi Zhang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 1931 KiB  
Review
Beyond bNAbs: Uses, Risks, and Opportunities for Therapeutic Application of Non-Neutralising Antibodies in Viral Infection
by Kahlio Mader and Lynn B. Dustin
Antibodies 2024, 13(2), 28; https://doi.org/10.3390/antib13020028 - 03 Apr 2024
Viewed by 739
Abstract
The vast majority of antibodies generated against a virus will be non-neutralising. However, this does not denote an absence of protective capacity. Yet, within the field, there is typically a large focus on antibodies capable of directly blocking infection (neutralising antibodies, NAbs) of [...] Read more.
The vast majority of antibodies generated against a virus will be non-neutralising. However, this does not denote an absence of protective capacity. Yet, within the field, there is typically a large focus on antibodies capable of directly blocking infection (neutralising antibodies, NAbs) of either specific viral strains or multiple viral strains (broadly-neutralising antibodies, bNAbs). More recently, a focus on non-neutralising antibodies (nNAbs), or neutralisation-independent effects of NAbs, has emerged. These can have additive effects on protection or, in some cases, be a major correlate of protection. As their name suggests, nNAbs do not directly neutralise infection but instead, through their Fc domains, may mediate interaction with other immune effectors to induce clearance of viral particles or virally infected cells. nNAbs may also interrupt viral replication within infected cells. Developing technologies of antibody modification and functionalisation may lead to innovative biologics that harness the activities of nNAbs for antiviral prophylaxis and therapeutics. In this review, we discuss specific examples of nNAb actions in viral infections where they have known importance. We also discuss the potential detrimental effects of such responses. Finally, we explore new technologies for nNAb functionalisation to increase efficacy or introduce favourable characteristics for their therapeutic applications. Full article
(This article belongs to the Special Issue Review Collection on Humoral Immunity)
Show Figures

Figure 1

Back to TopTop